Search results
Results From The WOW.Com Content Network
The NHS e-Referral Service (ERS) is an electronic referral system developed for the Health and Social Care Information Centre by IT consultancy BJSS. It is used by NHS England and it replaced the Choose and Book service on 15 June 2015. [ 1 ]
The e-referral project was put in place to allow for a more cost-effective way of treating a bigger number of patients, increase productivity and to improve access to healthcare. There were two hundred general practitioner practices and one million residents originally involved in the project.
The NHS and DXC Technology initiated negotiations for a new whole-of-system EHR in 2010. Despite the National Programme for IT being wound up by the UK Department of Health and Social Care, the department announced that it would enter into an agreement with DXC to supply Lorenzo to NHS trusts under a Standing Order Arrangement.
The NHS App allows patients using the National Health Service in England to book appointments with their GP, order repeat prescriptions and access their GP record. Available since late 2018, the app was developed by NHS Digital and NHS England. [1] The health ministers Jeremy Hunt and Matt Hancock both stressed their support for the project.
GOV.UK Verify was an identity assurance system developed by the British Government Digital Service (GDS) which was in operation between May 2016 and April 2023. The system was intended to provide a single trusted login across all British government digital services, verifying the user's identity in 15 minutes. [1]
Elon Musk and Vivek Ramaswamy aim to cut $2 trillion from the federal budget by July 4, 2026. They've said they'll fire federal employees, "delete" agencies, and publicize all of their work.
Mental health services were not integrated with physical health services when the NHS was established in 1948. Shortages of money, staff and buildings continued. Confederation of Health Service Employees organised an overtime ban in 1956, the first national industrial action in the NHS.
This strong market position generates substantial cash flows that support shareholder returns. Turning to the specifics, the pharmaceutical giant offers investors a 4.3% dividend yield backed by a ...